Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Hydroxycarbamide 500mg capsules
0801050P0AAAAAA
|
Hydroxycarbamide | Hydroxycarbamide | Malignant Disease and Immunosuppression | 18,497 |
|
Hydrea 500mg capsules
0801050P0BBAAAA
|
Hydrea | Hydroxycarbamide | Malignant Disease and Immunosuppression | 780 |
|
Hydroxycarbamide 500mg/5ml oral solution sugar free
0801050P0AAAEAE
|
Hydroxycarbamide | Hydroxycarbamide | Malignant Disease and Immunosuppression | 209 |
|
Hydroxycarbamide 1g tablets
0901030R0AAAAAA
|
Hydroxycarbamide (Sickle Cell) | Hydroxycarbamide | Nutrition and Blood | 146 |
|
Hydroxycarbamide 100mg tablets
0901030R0AAABAB
|
Hydroxycarbamide (Sickle Cell) | Hydroxycarbamide | Nutrition and Blood | 62 |
|
Hydroxycarbamide 500mg/5ml oral suspension
0801050P0AAADAD
|
Hydroxycarbamide | Hydroxycarbamide | Malignant Disease and Immunosuppression | 17 |
|
Xromi 100mg/ml oral solution
0801050P0BDAAAE
|
Xromi | Hydroxycarbamide | Malignant Disease and Immunosuppression | 14 |
|
Hydroxycarbamide 500mg/5ml oral solution
0801050P0AAABAB
|
Hydroxycarbamide | Hydroxycarbamide | Malignant Disease and Immunosuppression | 11 |
|
Siklos 1000mg tablets
0901030R0BBAAAA
|
Siklos | Hydroxycarbamide | Nutrition and Blood | 3 |
|
Siklos 100mg tablets
0901030R0BBABAB
|
Siklos | Hydroxycarbamide | Nutrition and Blood | 1 |
|
Droxia 300mg capsules
0801050P0BCAAAC
|
Droxia | Hydroxycarbamide | Malignant Disease and Immunosuppression | No data available |
|
Hydroxycarbamide 300mg capsules
0801050P0AAACAC
|
Hydroxycarbamide | Hydroxycarbamide | Malignant Disease and Immunosuppression | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.